Is Regeneron a Buy After the FDA Approved Its Gene Therapy to Restore Hearing?

Why It Matters

Regeneron's diversified pipeline and strategic pricing moves offset eye‑drug headwinds, positioning the biotech for continued revenue expansion and making its current valuation attractive to investors.

Key Takeaways

• Q1 revenue rose 19% to $3.6 billion, beating estimates.
• Eylea sales fell 10% to $941 million, offset by Eylea HD growth.
• Dupixent generated $1.6 billion, up 36% YoY, expanding indications.
• Otarmeni received FDA accelerated approval, offered free in U.S.
• Regeneron launched $3 billion share buyback, P/E ~16.5.

Pulse Analysis

Regeneron’s first‑quarter earnings underscored the resilience of its broader portfolio despite a softening in the ophthalmology segment. Revenue jumped 19% to $3.6 billion, propelled by robust performance from its oncology drug Libtayo and the multi‑indication biologic Dupixent, which posted $1.6 billion in sales, up 36% year‑over‑year. While Eylea’s overall sales slipped 10% amid competition from Roche’s Vabysmo, the premium Eylea HD formulation grew 52%, hinting at a potential rebound as physicians adopt the higher‑dose product. The earnings beat helped the company justify a fresh $3 billion share‑repurchase program, reinforcing confidence in cash flow generation.

The FDA’s accelerated approval of Otarmeni marks Regeneron’s entry into the emerging gene‑therapy space for hearing loss. The therapy, targeting OTOF gene variants, will be provided at no cost in the United States, a strategic move designed to secure favorable pricing terms for Regeneron’s broader portfolio. By agreeing to align Medicaid pricing with most‑favored‑nation levels, the company shields itself from future government price controls while retaining the ability to charge market rates abroad. This maneuver not only expands Regeneron’s therapeutic reach but also demonstrates a savvy approach to navigating pricing pressures in the biotech industry.

From a valuation perspective, Regeneron trades at roughly a 16.5× forward P/E, a discount to historical averages and many high‑growth peers. The firm plans to invest $6 billion in R&D in 2026, reflecting confidence in its late‑stage pipeline, which includes more than 50 candidates and 34 in phase 2/3 trials, such as GLP‑1 weight‑loss agents and the melanoma combo fianlimab‑cemiplimab. Coupled with a 76% gross margin and a strong cash position, the modest valuation and ongoing share‑buybacks suggest the recent stock dip may be an overreaction, presenting a potential entry point for investors seeking exposure to a diversified biotech with solid growth drivers.